Compare GSK plc (GSK) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs TORM plc — how do they compare? GSK plc trades at $52.79 (market cap $101.34B), while TORM plc trades at $29.88 (market cap $2.97B). The key difference: GSK plc is far larger — about 34.1× TORM plc's market cap, and TORM plc pays the higher dividend (9.45%). Which is the better fit depends on your goals.
| GSK | TRMD | |
|---|---|---|
Market Cap | $101.34B | $2.97B |
Sector | Health | Technology |
52-Week High | $61.18 | $34.87 |
52-Week Low | $36.20 | $17.50 |
Enterprise Value | $121.95B | $3.86B |
Dividend Yield | 3.49% | 9.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
TRMD trades at $29.77, up 1.17% today, with strong technical momentum showing bullish moving averages and support at $29. The company demonstrates robust fundamentals with a P/E of 8.69, net margin of 24.41%, and consistent dividend payments including the upcoming $0.70 distribution. Recent earnings showed mixed results with a Q4 beat but Q1 miss against expectations.
TRMD presents a compelling value opportunity with attractive valuation metrics and strong profitability, though near-term volatility and earnings consistency remain key considerations. The unanimous analyst buy rating and bullish technical setup support upside potential, while investors should monitor execution on Q2 expectations and tanker market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
